Kaposi's sarcoma (KS)-associated herpes virus (KSHV) is the causative agent of primary effusion lymphoma and of KS. Primary effusion lymphoma (PEL) is an aggressive proliferation of B cells. Conventional chemotherapy has limited benefits in PEL patients, and the prognosis is very poor. We previously reported that treatment of human T-cell leukemia virus type 1 (HTLV-1)-associated adult T-cell leukemia/lymphoma cells either with arsenic trioxide (As) combined to interferon-a (IFN-a) or with the bortezomib (PS-341) proteasome inhibitor induces cell cycle arrest and apoptosis, partly due to the reversal of the constitutive nuclear factor-jB (NF-jB) activation. PEL cells also display an activated NF-jB pathway that is necessary for their survival. This prompted us to investigate the effects of PS-341, or of the As/IFN-a combination on PEL cells. A dramatic inhibition of cell proliferation and induction of apoptosis was observed in PS-341 and in As/IFN-a treated cells. This was associated with the dissipation of the mitochondrial membrane potential, cytosolic release of cytochrome c, caspase activation and was reversed by the z-VAD caspase inhibitor. PS-341 and As/IFN-a treatment abrogated NF-jB translocation to the nucleus and decreased the levels of the anti-apoptotic protein Bcl-X L . Altogether, these results provide a rational basis for a future therapeutic use of PS-341 or combined As and IFN-a in PEL patients.
Introduction
Infection with Kaposi's sarcoma (KS)-associated herpesvirus (KSHV) or human herpesvirus type 8 (HHV-8), 1 is linked to all forms of KS, to primary effusion lymphoma (PEL), [2] [3] [4] to some forms of multicentric Castelman's disease (MCD) 5, 6 as well as to other solid lymphomas. [7] [8] [9] KSHV is a g-2 herpesvirus that infects multiple cell types. Infection of circulating mononuclear cells, particularly B cells, provides a reservoir for latent virus and participates in the viral dissemination. Infection of endothelial cells of lymphatic origin leads to the development of KS. PEL or body cavity-based lymphoma is a high-grade B-cell malignancy that belongs to the group of non-Hodgkin's B-cell lymphomas (NHL). It is estimated that PEL accounts for 3% of all HIV-related NHL. 10 PEL is characterized by pleural, pericardial or peritoneal lymphomatous effusions in the absence of a solid tumor mass. 11, 12 The presence of KSHV genome in PEL cells, in addition to the fact that a number of KSHV-encoded viral proteins have been shown to possess transforming ability, 13 strongly suggests that KSHV contributes to the B-cell transformation. 14 Of note, PEL cells are very often also coinfected with Epstein-Barr virus (EBV). 15 A number of drugs have been shown to induce apoptosis in KSHV-infected PEL cells. [16] [17] [18] [19] The combination of interferon-a (IFN-a) and zidovudine (AZT) induced apoptosis in PEL cell lines and in non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice inoculated with these cells. [20] [21] [22] Rapamycin (sirolimus) has also been shown to be effective in PEL, both in vitro and in a xenograft mouse model, through the inhibition of autocrine signaling. 23 Nevertheless, in vivo, PEL patients rarely respond to conventional systemic chemotherapy and their prognosis is poor, with a median survival time of less than 6 months. 24 Several alternative treatments have now been tested in limited series of patients, including high-dose chemotherapy and autologous stem cell transplantation. 24, 25 A chemotherapy regimen that includes high-dose methotrexate was shown to induce complete remission in a number of AIDS-associated PEL patients. 26 Moreover, intrapleural cidofovir showed some benefit in one patient. 27 Importantly, a recent study demonstrated that the two prognostic factors associated with unfavorable clinical outcome are a poor performance status and the absence of highly active antiretroviral therapy (HAART) before PEL diagnosis. 28 The nuclear factor-kB (NF-kB) transcription factor plays an important role in cancer development and progression (for a review see Karin 29 ). The NF-kB pathway is constitutively activated in latently KSHV-infected PEL cells 30 due to the interaction of the KSHV-latent protein v-FLIP with the cellular TRAF and IkB-kinase (IKK) proteins. 31, 32 Inhibiting the NF-kB pathway in PEL cells has been shown to result in apoptosis, 30, 33 demonstrating that this pathway is critical for the survival of PEL cells.
Arsenic trioxide (As) is a very effective treatment of acute promyelocytic leukemia (APL). 34 APL represents a distinct subtype of acute myeloid leukemia that is characterized by unique clinical characteristics and a specific cytogenetic abnormality, t (15;17) , which results in a reciprocal translocation between the PML gene on chromosome 15 and the retinoic acid receptor-a (RAR-a) gene on chromosome 17.
35,36 Adult T-cell leukemia (ATL) is a highly aggressive lymphoproliferative disorder of activated CD4 þ T lymphocytes, resulting from infection by the human T-cell leukemia virus type 1 (HTLV-1), and associated with a poor prognosis. 37 We have previously shown that As synergizes with IFN-a to induce cell cycle arrest and apoptosis in ATL cells. [38] [39] [40] [41] At the molecular level, the combination of As/IFN-a specifically induces proteosomal degradation of the HTLV-1 oncoprotein Tax and reversal of NF-kB activation. 39, 41, 42 The results of a phase II clinical trial in relapsed/refractory ATL patients demonstrate that As has striking antileukemic effects. 43 Bortezomib (PS-341) is a selective inhibitor of the 26S proteasome, a critical nuclear and cytoplasmic proteolytic system that regulates cell proliferation, differentiation and apoptosis. 44 The ubiquitin-proteasome pathway normally eliminates intracellularly damaged, mutant and misfolded proteins, and a variety of short-lived functional proteins such as cyclins and cyclin-dependent kinase inhibitors, NF-kB inhibitors and p53. PS-341 has demonstrated clinical effect in hematological malignancies and solid tumors. 45 Strikingly, PS-341 induces a high response rate in relapsed or refractory multiple myeloma. 46 Although PS-341 antitumor activity correlates with suppression of NF-kB activity, it also affects many intracellular regulatory molecules. 47, 48 We and others have shown that clinically achievable concentrations of PS-341 induce growth inhibition, cell cycle arrest and apoptosis in ATL-derived cells as well as in transplanted animals. [48] [49] [50] This effect is associated with the stabilization of IkBa, IkBb, IkBe, p21, p27 and p53 proteins, and selective inhibition of p65/Rel-A DNA-binding NF-kB complexes.
The fact that persistent NF-kB activity is critical for PEL-cell survival prompted us to study the effect of the NF-kB inhibitors, PS-341 as well as the combination As and IFN-a, on KSHVinfected PEL cells. Our data demonstrate that PS-341, and As combined to IFN-a, exert a potent inhibitory effect on the cell proliferation, and induce caspase-dependent apoptosis in KSHV-infected PEL cells. Our results provide a rational basis for the therapeutic use of PS-341, or combined As and IFN-a, in PEL patients.
Materials and methods

Cells, drugs and antibodies
BC-3 and BCBL-1 cell lines are KSHV þ /EBV À malignant B cells derived from PEL patients 51, 52 and were obtained from American Type Culture Collection (Manassas, VA, USA). Cells were grown in RPMI-1640 medium containing 10% heat-inactivated fetal calf serum (FCS) and antibiotics. Cell concentration of 1 Â 10 5 cells/ml was chosen for seeding in all experiments. Cells were grown in 96-well plates (Nunc, Naperville, IL, USA), and drugs were added at the indicated concentrations at the initiation of cultures for 24, 48 or 72 h. Cell growth was assessed by cell count using trypan blue dye exclusion protocols, and the CellTiter 96 cell proliferation assay kit (Promega Corp., Madison, WI, USA).
Recombinant IFN-a (Hoffman-La Roche, Basel, Switzerland) and As were prepared as stock solutions in normal saline. Working stocks were diluted in RPMI-1640 culture medium (Gibco-BRL, Gaithersburg, MD, USA), supplemented with 10% heat-inactivated FCS (Gibco-BRL). PS-341 was purchased from Millenium Pharmaceuticals (Cambridge, MA, USA). The caspase inhibitor z-VAD was obtained from Bachem Bioscience (King of Prussia, PA, USA). Cells were treated with either therapeutic doses of PS-341 (10 nM), As (1 mM) or IFN-a (1000 IU), or combination of As/IFN-a for up to 72 h. DNA content analysis. Cells were harvested, washed twice with cold phosphate buffered saline (PBS), fixed in cold (À201C) 100% ethanol and kept overnight at 41C. Subsequently, cells were rinsed with PBS, treated with Tris-HCl buffer (pH 7.4) containing 1% Rnase, and stained with PI at 100 mg/ml (final concentration). Distribution of cell cycle phases with different DNA contents was determined using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). In each sample, 10 000 non-gated events were acquired. Analysis of cell cycle distribution (including apoptosis) was performed using the CellQuest software (Becton Dickinson).
Measurement of cytochrome c release
Cytochrome c release was measured using the cytochrome c enzyme-linked immunosorbent assay (ELISA) kit (EMD Biosciences, Darmstadt, Germany). To determine the distribution of cytochrome c in treated cells, subcellular fractionation was performed before solubilization as previously described. 53 Subsequently, apoptotic cytochrome c was measured in the cytosolic fraction according to the manufacturer's instructions. Cytochrome c levels were assayed by optical density (OD) measurement at 450 nm using an ELISA microplate reader. Apoptotic cytochrome c levels were calculated from duplicate measurements and are expressed as percentage increase over control set as one.
Caspase activation assays
Caspase activity was measured using the ApoTarget Caspase Colorimetric Assay Sampler Kit (Biosource International, Camarillo, CA, USA) according to the manufacturer's instructions. We detected caspase activity by measuring the cleavage of synthetic substrates upon their incubation with lysates of apoptotic cells. These former substrates contain tetrapeptide sequences mimicking the cleavage site of the various substrate subgroups. Caspase-2, -3, -6, -8 and -9 activities were assayed by OD measurement at 405 nm using an ELISA microplate reader.
Immunoblot analysis
Cells were solubilized at 41C in lysis buffer consisting of 0.125 M Tris-HCl (pH 6.8), 2% SDS, 2.5% b-mercaptoethanol and 10% glycerol. Protein concentration was determined by the Bio-Rad Dc protein assay, and 30 mg of proteins was loaded onto a 12% SDS-polyacrylamide gel, subjected to electrophoresis, and transferred onto nitrocellulose membranes. After blocking of the membrane in 5% skimmed milk in TBS containing 0.05% Tween-20, the blots were incubated with specific antibodies. The blots were washed and protein bands were visualized using the ECL chemiluminescence system (Amersham, Buckinghamshire, UK).
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as described. 39, 41, 42 Briefly, cells were lysed, nuclei were collected by centrifugation, extracted by gentle mixing for 30 min at 41C, followed by centrifugation at 14 000 r.p.m. Protein concentration was determined using the BioRad assay (Bio-Rad Laboratories, Hercules, CA, USA). NF-kB consensus oligonucleotide (Santa Cruz Biotechnology Inc.) was end-labeled with g-32 P-ATP using T4 polynucleotide kinase. Hybridization reaction was performed using 10-20 mg of nuclear extract, 1 mg of poly(dI.dC), 1 mg of poly(dN6) as nonspecific competitor, and 10 mg of bovine serum albumin in 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 50 mM KCl, 1 mM ethylenediamine tetraacetic acid (EDTA) and 5 mM dithiothreitol (DTT). The reaction mixture was run on a 5% non-denaturing polyacrylamide gel, dried at 801C under vacuum for 2 h on Whatman filter paper, and processed for autoradiography. Specific NF-kB bands were determined by competition experiments using a mutant oligonucleotide that has lost its ability to bind to the transcription factor.
Results
As/IFN-a combination or PS-341 treatment induced growth arrest of PEL cells
Different drug combinations were added to two KSHV-infected PEL-derived cell lines (BC-3 and BCBL-1). Cell growth was assessed by cell count using trypan blue dye exclusion protocols and the CellTiter 96 cell proliferation assay kit. Cells were treated with either therapeutic doses of PS-341 (10 nM), As (1 mM), IFN-a (1000 IU), or combination of As/IFN-a for up to 72 h. Upon treatment with PS-341, both BC-3 and BCBL-1 underwent a significant drop in cell proliferation at 24 h and complete growth inhibition at 48 h (Figure 1a) . On the other hand, treatment with IFN-a alone had only a moderate inhibitory effect at 24 h but a more profound one at 48 and 72 h, and treatment with As alone resulted in growth inhibition at 24 h, and even more so at 48 and 72 h. Interestingly, strong synergy was observed when cells were treated with a combination of As and IFN-a: proliferation of As/IFN-a-treated BCBL-1 and BC-3 cells was strongly reduced at 24, 48 and 72 h in comparison with either As alone-or IFN-a alone-treated cells (Figure 1a) . These results are quite similar to the previously reported synergy observed between As and IFN-a in HTLV-1-positive ATL cells.
Effects of PS-341, IFN-a, As and As/IFN-a combination on the cell cycle
The cellular DNA contents distribution by FACS analysis upon cell treatment was then examined. After 24 h of treatment, PS-341, the combination of As and IFN-a, and to a lesser extent As, but not IFN-a, induced a significant increase in the sub-G 1 region (Figure 1b , white boxes) in both cell lines. These cells can be considered as dying from apoptosis. The percentage of pre-G 0 /G 1 BC-3 cells further increased at 48 h of PS-341 treatment. As seen in Figure 1b , a clear synergy between As and IFN-a was observed in both cell lines. We also assessed changes in the cell cycle distribution in non-apoptotic cells. Figure 1b represents the relative distribution of non-apoptotic cells between noncycling (G 0 /G 1 phases; black boxes) and cycling cells, (the sum of S and G 2 /M phases; dashed boxes). Minimal changes in cell cycle distribution were observed in BC-3 or BCBL-1 cells treated with As alone, IFN-a alone or PS-341 alone. However, the combination of As and IFN-a sharply diminished the number of cycling living cells, particularly in BC-3 cells (Figure 1b) .
As/IFN-a combination or PS-341 treatment induce apoptosis of PEL cells
To confirm that the observed increase in the pre-G 0 /G 1 results from apoptosis, both cell lines were analyzed using double staining (DAPI/annexin V), after 48 h exposure to the different treatments (Figure 2a and not shown). Apoptotic cells were detected as annexin V þ /PI À whereas dead cells were PI þ . A significant increase in the apoptotic population (PS exposure, left panel) was detected when either PS-341 or a combination of As and IFN-a were added to the cell culture. BCBL-1 cells are more sensitive to the drug treatments than BC-3, as evidenced by the decrease in the percentage of viable cells (data not shown). A similar experiment was also performed with acridine orange staining (Figure 2b ). This allows the evaluation of the percentage of DNA degradation, which is a hallmark of apoptosis. Consistent with the above results, As/IFN-a and PS-341 treatments significantly increased the percentage of DNA degradation in both cell lines (Figure 2b and data not shown).
PS-341 and As/IFN-a-induced apoptosis is caspasedependent in PEL cells
We then investigated whether the observed apoptosis was due to caspase activation or not. Cell extracts were obtained after various treatments and processed for western blot. After 48 h, PS-341 treatment resulted in complete cleavage of procaspase-3, -8 and -9 in BC-3 cells (Figure 3a) . Similar results were observed with BCBL-1 cells (data not shown). Arsenic alone induced partial cleavage of procaspase-3, -8 and -9, whereas IFN-a alone had no significant effect. The combination of As and IFN-a resulted in a complete cleavage of procaspase-3, -8 and -9, concordant with their synergistic effect on apoptosis induction (Figure 3b ). Consistent with these results, PS-341-induced caspase activation was associated with complete PARP cleavage, both in BC-3 ( Figure 3c ) and BCBL-1 (not shown). Similarly, partial PARP cleavage was observed with As or IFN-a and complete cleavage was observed with the combination of As and IFN-a (Figure 3d) .
Caspase activation was also measured by ELISA, as described in Materials and methods (Figure 3e ). PS-341 treatment resulted in activation of caspases in both BC-3 ( Figure 3e ) and BCBL-1 (data not shown) cell lines. In PS-341-treated cells, caspase-2, -3, -6, -8 and -9 activities were induced after 24 h by 3-5-fold in BC-3 cells (Figure 3e ), and by 3-8-fold, in BCBL-1 cells (data not shown). In contrast, treatment with As or IFN-a alone resulted in a moderate caspase activation: caspase-2, -3, -6, -8 and -9 activities were induced by 1.5-2-fold after 24 h treatment with As, and by 2-3-fold after 24 h treatment with IFN-a in both BC-3 and BCBL-1 cells (Figure 3e and data not shown). The combined treatment with As and IFN-a displayed a dramatic synergistic effect on caspase activation. In As/IFN-a-treated cells, caspase-2, -3, -6, -8 and -9 activities were induced 4-8-fold after 24 h in BC-3 cells, and 3-6-fold after 24 h in BCBL-1 cells (Figure 3e and data not shown). Ultimately, both cell lines were treated with z-VAD, a broad caspase inhibitor, in the presence of the different drugs. Incubating BC-3 (Figure 3f ) or BCBL-1 cells (data PEL cells treatment with arsenic and bortezomib R Abou-Merhi et al not shown) with z-VAD during treatment with As/IFN-a or with PS-341, significantly protected KSHV-infected cells from dying. Altogether, these results clearly demonstrate that caspase activation plays a central role in PS-341 or As/IFN-a-induced apoptosis of PEL-derived cells.
PS-341 and As/IFN-a-induced mitochondrial-mediated apoptosis
To assess for mitochondrial involvement in PS-341-or As/IFN-ainduced apoptosis, DC m was measured in BC-3 ( Figure 4a ) and BCBL-1 cells (data not shown). As or As/IFN-a-treated cells that entered apoptosis showed altered mitochondrial membrane permeability that leads to DC m collapse. Similarly, PS-341 treatment induced a 70-90% loss of the DC m in both cell lines. The observed DC m collapse, secondary to altered mitochondrial membrane permeability, suggests that caspase activation may result from activation of the endogenous pathway of apoptosis, associated with cytochrome c release. Indeed, ELISAs demonstrated that PS-341 and As/IFN-a treatments resulted in cytochrome c release in BC-3 and BCBL-1 (Figure 4b and data not shown). These results indicate that PS-341 and As/IFN-a-induced apoptosis of KSHV-infected PEL cells is associated with dissipation of mitochondrial membrane potential and cytochrome c release.
PS-341 and As/IFN-a treatments of PEL cells reversed the constitutive NF-kB activation and downregulated the protein level of Bcl-X L
We have previously shown that both As/IFN-a and PS-341 treatments reverse the constitutive activation of the NF-kB pathway in HTLV-1-infected ATL cells. 39, 41, 42, 48 As mentioned above, the NF-kB pathway is constitutively activated in KSHVinfected cells, mostly through interaction of the viral protein v-FLIP with the cellular proteins TRAF and IKK. To explore the effect of As/IFN-a and PS-341 treatments on the NF-kB pathway in KSHV-infected cells, we performed retardation gels (EMSA) using a NF-kB-specific probe. One predominant positive complex ( Figure 5, lane 4) was detected by the 32 P-labeled NF-kB consensus oligonucleotide. This complex disappeared in the presence of excess of unlabeled NF-kB consensus oligonucleotide (lane 2), but not with excess unlabeled mutant oligonucleotide (lane 3), confirming its specificity. Both As/ IFN-a (lane 7) and PS-341 (lane 8) treatments were able to inhibit the constitutive NF-kB in PEL cells.
Activation of the mitochondrial-mediated endogenous pathway of apoptosis is regulated by Bcl-2 family members, including Bcl-X L whose promoter is NF-kB-dependent. We therefore measured the level of expression of Bax, Bcl-X L and Bcl-2 after drug treatment using whole cell extracts from BC-3 cells (Figures 6a and b) . Minimal changes in the protein levels of Bax and Bcl-2 were observed after As/IFN-a or PS-341 treatment. Strikingly, we noted a strong decrease in Bcl-X L expression after As/IFN-a or PS-341 (Figures 6a and b) . GAPDH western blot confirmed equal loading of protein extracts. Use of IFN-a alone or in combination with other drugs has held promise for the treatment of several hematological malignancies and solid tumors. We show that IFN-a alone significantly impaired growth of PEL cells. Interestingly, this IFN-a effect was not previously observed in HTLV-1-infected ATL cells. 38, 41 On note, there is at least one report in the literature of a PEL patient who responded to IFN-a. 22 Furthermore, the combination of IFN-a and AZT induced apoptosis in PEL cell lines and in NOD/SCID mice inoculated with these cells. [20] [21] [22] On the other hand, As is known to be a very effective treatment of APL, and promising for treatment of ATL, particularly when combined with IFN-a. 43 Although, the molecular mechanism by which the combination As/IFN-a exerts its effects is still under investigation, the drastic cooperation of these two agents in PEL is evident. Indeed, following treatment of HHV-8-infected cell lines, the cell proliferation was impeded in a highly synergistic manner between As and IFN-a. This dramatic synergy between As and IFN-a in KSHV-infected PEL cells is reminiscent of their synergy in HTLV-I-infected ATL cells.
Studies addressing the molecular basis of the action of As have been somehow conflicting. In APL cells, initial studies suggested that As action results in the downregulation of the anti-apoptotic protein Bcl-2. At the cellular level, studies conducted on the APL-derived cell line (NB4) showed that As triggers apoptosis at a micromolar concentration (reviewed in Zhu et al. 54 ). However, lower doses of arsenic were shown to induce differentiation of the leukemic cells instead of apoptosis (reviewed in Zhu et al.
54
). At the molecular level, As specifically leads to the degradation of the PML/RARa oncoprotein, 55 whereas IFN-a activates the transcription of the PML gene. In ATL cells, at the molecular level, As/IFN-a combination specifically induces proteosomal degradation of the HTLV-1 oncoprotein Tax and reversal of NF-kB activation. 39, 41, 42 Here we show that the combination of As/IFN-a reversed the constitutive activation of NF-kB, and downregulated Bcl-X L , similarly explaining the observed mitochondrial-mediated, caspase-dependent apoptosis in PEL cells.
The proteasome inhibitor PS-341 has demonstrated clinical effect in both hematological malignancies [56] [57] [58] and solid tumors. 59, 60 Although PS-341 antitumor activity correlates with suppression of NF-kB activity, 46 it also affects many intracellular regulatory molecules such as p53, p21 and p27, 57, 61 blocks the anti-apoptotic effects of bcl-2 and sensitizes murine myeloid leukemia cells to TRAIL-mediated apoptosis. 47 We have previously shown that PS-341 treatment of HTLV-I-negative malignant T cells had a variety of effects at the molecular level. It significantly downregulated the anti-apoptotic protein X-IAP and to a lesser extent c-IAP-1 and Bcl-X L . It also induced ceramide accumulation, and resulted in a significant loss of mitochondrial membrane potential and caspase activation. 48 In ATL-derived cells, we and others have shown that PS-341 treatment resulted in a dramatic stabilization of IkB-a, IkB-b and IkB-e proteins, and reversal of NF-kB activation. [36] [37] [38] In this study, we show that PS-341 treatment of PEL cells reversed the constitutive activation of NF-kB, downregulated Bcl-X L , similarly explaining the observed mitochondrial-mediated, caspasedependent apoptosis.
NF-kB activation, one of the hallmarks of KSHV-induced transformation, 30 was dramatically reduced by both As/IFN-a and PS-341 treatments. Previous studies clearly established the importance of NF-kB activation in both KSHV-induced transformation and resistance to apoptosis. 30, 31, 33 Treatment with the NF-kB inhibitor Bay 11-7082 selectively inhibits IkBa phosphorylation and constitutively inhibits NF-kB DNA-binding activity in KSHV-infected PEL cells, and induces mitochondrial-mediated apoptotic cascades. In a murine model of PEL, treatment with Bay 11-7082 resulted in NF-kB inhibition in vivo, and significantly delayed the onset and development of KSHV-infected lymphomas. 30 These results suggest that inhibition of NF-kB may be an effective treatment for KSHV-infected lymphomas through the downregulation of specific pro-survival factors that protect the virally infected lymphoma cells from apoptotic stimuli. NF-kB appears to be a major target of IFN-a/ As combination or PS-341, but the pathway triggered by these drugs in PEL cells is still obscure, and the exact NF-kB target genes implicated in apoptosis control have not been identified. The anti-apoptotic protein, Bcl-X L , whose promoter is NF-kBdependent, represents an ideal target, since its protein level was dramatically reduced by both As/IFN-a and PS-341 treatments.
Both PS-341 and the combination As/IFN-a induced dissipation of mitochondrial membrane potential, cytochrome c release and caspase activation, suggesting the involvement of the mitochondrial-mediated endogenous pathway of apoptosis. Importantly, As/IFN-a-and PS-341-induced apoptosis was partially but significantly reversed by caspase inhibitors which inhibit cell cycle progression in T and B lymphocytes. 62, 63 Hence, the protective effect of z-VAD in As/IFN-a-or PS-341-treated KSHV-infected cells, demonstrate the involvement of caspase activation in the observed apoptosis.
PEL remains of poor prognosis. Novel effective drugs are warranted to improve morbidity and mortality and to reduce the emergence of resistant clones. Wu and collaborators 21 recently demonstrated that NOD/SCID mice can be used for evaluating new PEL treatments. If our in vitro results are confirmed in this model, this will strongly support the development of a phase II clinical study for the treatment of KSHV-associated PEL by PS-341 or the combination of As and IFN-a.
